Velocity Clinical Research, Inc.

Here's a great example of what community outreach can do to improve lives, even beyond the clinic. Our Durham site currently has elementary teachers enrolled in clinical trials. During a recent visit, they were discussing the need for books in their classrooms with Joseph Henderson, our community liaison in Durham. After Joseph talked to a few of his connections, 150 brand new books arrived at the clinic for us to donate. Half will go to a local school, and the other half will go to a local homeless shelter or family crisis shelter. #CommunityOutreach #ClinicalResearch

Congratulations to Pfizer and Moderna on receiving EUA on their updated mRNA COVID-19 vaccines. We would also like to congratulate and thank all sites, patients, and investigators who continue to support COVID-19 research.

Since launching in-app stipend payments, Velocity has paid more than $2 million to patients globally through VISION. The mobile app has also contributed to more than 2,500 patient randomizations, empowering users to get matched with clinical trials, self-screen, and self-schedule visits, all at times that are most convenient for them. Together, VISION Engage and VISION Recruit are making clinical trials more accessible for new patients and more enjoyable for current participants. #VISION #AI #ClinicalTrials

Cincinnati (Mt. Auburn) is our first to be featured in this monthly Velocity #SiteSpotlight! This dedicated site has conducted clinical trials for decades, and nearly every lipid-lowering therapy currently on the market was tested at the Mt. Auburn site over the last 25 years. Key staff: - PIs: Matthew Wenker, MD; Bain Butcher, MD, MFA - Sub-Is: Penny Stocker, MS, RN, FNP-BC, CNP; Katie Vale-Freeburg MSN, APRN, FNP-C, CNP - Regional Director: Kurt Percy - Site Director: Allison Deuel, CCRC Scroll through the images below to learn more about this site and see our staff!

Next month, Paul Evans will take part in a panel discussion at the DPHARM Conference in #Philadelphia. Moderated by Mark Travers of Merck, the panel will discuss if the consolidation of independent clinical trial sites into larger, integrated networks will bring new researchers and new locations into clinical research, and lead to reduced risk to Sponsors, increased predictability, streamlined site operations, and greater access for patients. Be sure to join this timely discussion if you’ll be at the conference. #DPHARM2024 #SiteNetworks #ClinicalResearch

A recent report from the Centers for Disease Control and Prevention shows that routine childhood vaccinations have prevented more than one million deaths in children born in the U.S. between 1994 and 2023. Without the clinical research behind these vaccines, hundreds of millions of people around the world would have been negatively impacted by the illnesses these vaccines prevent. This #ImmunizationAwarenessMonth, join us in thanking all those who helped bring these life-saving vaccines to fruition — especially our patients, PIs, staff, and clients. We are proud to say that over 90,000 people have joined vaccine and infectious disease trials at Velocity sites. Learn more about our impact on vaccine developments through the years: https://lnkd.in/gjvE8ERi Read more about this report: https://lnkd.in/eYWpu9mP

Another milestone for patients with primary biliary cholangitis (PBC)! Gilead’s Livdelzi® (seladelpar) has received accelerated FDA approval as a second-line treatment for PBC. Kris Kowdley, MD, was an author of the Phase 3 trial results published in the New England Journal of Medicine. Congratulations to Gilead, Dr. Kowdley, the team in Seattle, and the patients who supported the Phase 3 trial and ongoing research on seladelpar and PBC. Dr. Kowdley also made substantial contributions to the clinical research program that led to the accelerated FDA approval of Ipsen’s Iqirvo, a PBC treatment approved in June. Read the full press release: https://lnkd.in/dHMTs6vv #MASHCare #ClinicalTrials

The prevalence of MASLD and MASH is growing. As Nadege Gunn, MD, CPI, says, “Clinical research is really the opportunity we have to give our patients some hope and some perspective that their disease will one day soon be treatable.” As leaders of the Velocity MASH CARE Council, Dr. Gunn and Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, advise more than 20 sites conducting MASH clinical trials. As Dr. Kowdley explains, “[CARE Councils can] transfer the information and knowledge that someone like myself has accumulated over 30 years of doing research to sites that are capable, interested, and have the patient population.” Learn more about Velocity's MASH CARE Council: https://lnkd.in/g57vYKCf #CARECouncils #MASH #MASLD #Liver #Hepatology #Metabolic

Rick Fisher, Senior VP, Operations, is returning to the ACRP - Association of Clinical Research Professionals #Ride4DEI next month. Starting in 2021, Rick and Sergio Armani teamed up to complete this grueling journey through mountains and mud, venturing from Pittsburgh, PA, to Washington D.C., to raise funds to improve diversity and inclusion in the clinical research workforce. Over the past few years, the number of cyclists and the amounts raised have grown, providing ACRP educational scholarships — including attendance at the ACRP’s annual conference — for entry-level clinical research professionals from diverse communities. Consider joining Velocity in supporting this great initiative. Donate: https://lnkd.in/gaybZfRT

About a year after Lacanemab was approved by the FDA for the treatment of Alzheimer’s, we spoke with Robert Cupelo, MD, Principal Investigator at Velocity’s Syracuse, NY site about the drug’s impact and the future of Alzheimer’s disease treatment. “Just like leukemia and AIDS, the treatment for Alzheimer's is going to be a combination, a cocktail,” he muses. “Maybe one drug to get rid of the amyloid, plus an anti-inflammatory, or one of these medicines that block the enzyme so you can't make the amyloid anymore. That's the way we conquered AIDS, combinations that support each other.” Hear more from Dr. Cupelo: https://lnkd.in/gnjpVb_C #AlzheimersDisease #ClinicalResearch #CNS